A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV
A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg (Hydrocodone 5 mg/Acetaminophen 325 mg/Promethazine 12.5 mg) as a Treatment for Moderate-to-Severe Acute Pain and the Prevention of Opioid-Induced Nausea and Vomiting (OINV) Following Orthopedic Surgery
Sponsor: Charleston Laboratories, Inc
This PHASE3 trial investigates Nausea and Pain and is currently completed. Charleston Laboratories, Inc leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Apr 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2019 — Aug 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Charleston Laboratories, Inc
For direct contact, visit the study record on ClinicalTrials.gov .